A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC); Sponsor ¿ Memorial Sloan Kettering Cancer Center

Administered By

Contributors

Start/End

  • May 21, 2018 - February 28, 2020